Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

1.045 -0.085 (-7.52%)
Streaming Delayed Price Updated: 1:36 PM EDT, Oct 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,431,376
Open 1.120
Bid (Size) 1.040 (122)
Ask (Size) 1.050 (267)
Prev. Close 1.130
Today's Range 1.040 - 1.130
52wk Range 1.090 - 3.370
Shares Outstanding 348,875,959
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Agenus Inc.
Via Business Wire
HEICO, Canaan And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. HEICO Corporation (NYSE: HEI) shares tumbled 5.3% to $159.01... 
Via Benzinga

Performance

YTD
-56.46%
-56.46%
1 Month
-24.82%
-24.82%
3 Month
-31.25%
-31.25%
6 Month
-34.28%
-34.28%
1 Year
-50.00%
-50.00%

More News

Read More
3 Magnificent Growth Stocks to Buy on the Dip
Via The Motley Fool
Agenus to Participate in September Investor Conferences
From Agenus Inc.
Via Business Wire
Agenus (AGEN) Q1 2023 Earnings Call Transcript
Via The Motley Fool
Agenus Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers
From Agenus Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
SaponiQx Announces Breakthrough in Scaling Up of STIMULON™ Cultured Plant Cell Adjuvant
From SaponiQx
Via Business Wire
Agenus Reports Second Quarter 2023 Results
From Agenus Inc.
Via Business Wire
Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023
From Agenus Inc.
Via Business Wire
Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
From Agenus
Via Business Wire
Agenus Expands Executive Leadership Team
From Agenus Inc.
Via Business Wire
ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer
From Agenus
Via Business Wire
2 Low-Priced Stocks That Could Make You Richer
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2023
Via Benzinga
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
From Agenus Inc.
Via Business Wire
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Agenus Announces Virtual Annual Shareholders Meeting
From Agenus
Via Business Wire
Agenus to Participate in Jefferies Healthcare Conference
From Agenus
Via Business Wire
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
From Agenus Inc.
Via Business Wire
Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI
From Agenus
Via Business Wire
Agenus (NASDAQ: AGEN) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
Agenus to Present at the American Society of Clinical Oncology 2023 Annual Meeting
From Agenus
Via Business Wire
Agenus to Provide Corporate Update and First Quarter 2023 Financial Report
From Agenus
Via Business Wire
Agenus to Participate in May Investor Conferences
From Agenus
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.